|
Neoplasia
Citations 101-110 of 4217 total displayed.
|
Past content
(since Jan 1997):
|
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma
- Julia Kirshner, Kyle J. Thulien, Lorri D. Martin, Carina Debes Marun, Tony Reiman, Andrew R. Belch, and Linda M. Pilarski
Blood 2008; 112: 2935-2945.
[Abstract]
[Full text]
[PDF]
Central role of PI3K in transcriptional activation of hTERT in HTLV-I–infected cells
- Marcia Bellon and Christophe Nicot
Blood 2008; 112: 2946-2955.
[Abstract]
[Full text]
[PDF]
DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance
- Coralie Chaise, Sarah L. Buchan, Jason Rice, Jeanine Marquet, Hélène Rouard, Mathieu Kuentz, Gisella E. Vittes, Valérie Molinier-Frenkel, Jean-Pierre Farcet, Hans J. Stauss, Marie-Hélène Delfau-Larue, and Freda K. Stevenson
Blood 2008; 112: 2956-2964.
[Abstract]
[Full text]
[PDF]
ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy
- John K. C. Chan, Laurence Lamant, Elizabeth Algar, Georges Delsol, William Y. W. Tsang, King C. Lee, Karin Tiedemann, and Chung W. Chow
Blood 2008; 112: 2965-2968.
[Abstract]
[Full text]
[PDF]
Chromosomal translocations: revisited yet again
- Janet D. Rowley
Blood 2008; 112: 2183-2189.
[Full text]
[PDF]
Myeloproliferative disorders
- Ross L. Levine and D. Gary Gilliland
Blood 2008; 112: 2190-2198.
[Abstract]
[Full text]
[PDF]
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
- Ola Landgren, Lynn R. Goldin, Sigurdur Y. Kristinsson, Elin A. Helgadottir, Jan Samuelsson, and Magnus Björkholm
Blood 2008; 112: 2199-2204.
[Abstract]
[Full text]
[PDF]
Toll-like receptors: lessons to learn from normal and malignant human B cells
- David Chiron, Isabelle Bekeredjian-Ding, Catherine Pellat-Deceunynck, Régis Bataille, and Gaëtan Jego
Blood 2008; 112: 2205-2213.
[Abstract]
[Full text]
[PDF]
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
- Graham M. Mead, Sharon L. Barrans, Wendi Qian, Jan Walewski, John A. Radford, Max Wolf, Simon M. Clawson, Sally P. Stenning, Claire L. Yule, and Andrew S. Jack, on behalf of the UK National Cancer Research Institute Lymphoma Clinical Studies Group and the Australasian Leukaemia and Lymphoma Group
Blood 2008; 112: 2248-2260.
[Abstract]
[Full text]
[PDF]
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
- Brian G. Till, Michael C. Jensen, Jinjuan Wang, Eric Y. Chen, Brent L. Wood, Harvey A. Greisman, Xiaojun Qian, Scott E. James, Andrew Raubitschek, Stephen J. Forman, Ajay K. Gopal, John M. Pagel, Catherine G. Lindgren, Philip D. Greenberg, Stanley R. Riddell, and Oliver W. Press
Blood 2008; 112: 2261-2271.
[Abstract]
[Full text]
[PDF]
|
|
